News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Berlin, Germany, and Seattle, WA, USA

18.03.2011 | 110318_Press_release_Quest_Diagnostics

Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today informed that the colorectal cancer blood test ColoVantage™ developed and offered in the U.S. by its partner Quest Diagnostics Incorporated (NYSE:DGX) has been approved by the New York State’s Department of Health.

ColoVantage™ is based on Epigenomics’ proprietary DNA methylation technology andmSEPT9 biomarker licensed non-exclusively to Quest Diagnostics in 2008. New York State is the only State in the U.S. where laboratory-developed tests require explicit approval for patient testing. With this approval, ColoVantage™ is now available in the entire United States.

In a press release issued yesterday by Quest Diagnostics Jon R. Cohen, M.D., senior vice president and chief medical officer, Quest Diagnostics, commented:

“ColoVantage is a convenient, noninvasive option for the millions of patients 50 years of age and older who resist testing by recommended screening methods. As a technique that patients may actually use, ColoVantage is arguably the first practical testing option to promote meaningful cancer evaluation among this large underserved population. It is fitting that March, colorectal cancer awareness month, marks the date our test met New York’s rigorous regulatory criteria.”

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 0
pr@epigenomics.com
www.epigenomics.com

Notes to the Editor

Quest Diagnostics’ Press Release

Please find yesterday’s press release issued by Quest Diagnostics at
http://questdiagnostics.mediaroom.com/index.php?s=43&item=445

About Epigenomics

Epigenomics (www.epigenomics.com) is a cancer molecular diagnostics company developing and commercializing a pipeline of proprietary products. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.